Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
113427-24-0
Molecular formula
C809H1301N229O240S5
Molecular weight
~30400 g/mol
Drug class
Erythropoiesis-stimulating agent (ESA)recombinant human erythropoietin biologic
Mechanism of action
Binds erythropoietin receptors on erythroid progenitor cells in bone marrow, stimulating survival, proliferation and differentiation of erythroid precursors and increasing red blood cell production.
Indications / reported uses
Treatment of anaemia associated with chronic kidney disease in selected patients
Treatment of zidovudine-associated anaemia in selected patients with HIV infection
Treatment of anaemia in selected patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
Reduction of allogeneic red blood cell transfusion requirements in selected patients undergoing elective, non-cardiac, non-vascular surgery; indications are specific to the epoetin product label
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Epoetin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Epoetin Permitted Daily Exposure (PDE) report (the Epoetin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Epoetin Occupational Exposure Limit (OEL) report (the Epoetin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.